Toujeo (insulin glargine injection) was approved in 2015 and is an injectable long-acting insulin. It is used for adults with type 1 or type 2 diabetes to improve glycemic control. It is ...

There is good news for Mainers who rely on insulin according to our media partners WMTW. Maine Attorney General Aaron Frey ...

Sanofi's new insulin treatment Toujeo has shown its superiority in controlling blood sugar levels in patients in phase 3 trials. Toujeo is a new and improved formulation of Lantus (insulin ...

Sanofi's follow-up product to its insulin blockbuster Lantus has been approved in Europe. Toujeo (insulin glargine [rDNA origin]) has been approved for the treatment of type 1 and type 2 diabetes ...

Mainers who rely on insulin will now be eligible to purchase ... The products covered include Admelog, Lantus, Toujeo, Apidra and any biosimilar of those products that Sanofi markets in the ...

Toujeo, which provides a steady insulin release over 24 hours via a once-daily injection, has become an essential solution for individuals with type 1 and type 2 diabetes. Its efficacy in ...